Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Aug 16;20(9):1928–1936. doi: 10.1158/1055-9965.EPI-11-0236

Table 2.

Hazard ratios (HR) for prostate cancer-specific mortality associated with a panel of 22 single nucleotide polymorphisms (SNPs) in candidate genes in a discovery cohort (Seattle) and a validation cohort (Sweden)

Seattle Cohort Swedish Cohort
SNP Chr. Gene Alleles1 MAF2 HR 95% CI P-value
(q value)		 Model3 MAF2 HR 95% CI P-value4 Model3 P-value5
rs1137100 1p31 LEPR A/G 0.27 0.29 0.14–0.60 0.0001 (0.26) Dom: ACP 0.29 0.82 0.67–1.00 0.027 Dom: ACP 0.027
rs228697† 1p36 PER3 C/G 0.11 0.25 0.10–0.60 0.0002 (0.26) Dom: ACP
rs635261 1q25 RNASEL G/C 0.36 0.22 0.07–0.65 0.0007 (0.56) Rec: ACP 0.35 0.98 0.74–1.29 0.44 Rec: A 0.48
rs627839 1q25 RNASEL G/T 0.47 3.98 1.64–9.65 0.0004 (0.26) Dom: ACP 0.47 1.22 1.00–1.50 0.024 Dom: A 0.22
rs4583514 2p21 MSH2 G/A 0.38 2.49 1.21–5.10 0.01 (0.70) Dom: ACP 0.43 0.98 0.81–1.18 NS Dom: A NS
rs4608577 2p21 MSH2 T/G 0.17 2.04 1.36–3.07 0.002 (0.57) Tre: A 0.21 0.93 0.80–1.09 NS Tre: A NS
rs523349 2p23 SRD5A2 C/G 0.29 0.49 0.28–0.86 0.01 (0.66) Dom: A 0.32 1.15 0.94–1.40 NS Dom: ACP6 NS
rs12467911 2p23 SRD5A2 C/T 0.28 0.45 0.24–0.81 0.005 (0.57) Dom: A 0.32 1.16 0.95–1.41 NS Dom: ACP6 NS
rs11710277 3p21 SEMA3F A/G 0.09 3.71 1.75–7.90 0.001 (0.53) Dom: ACP 0.08 0.86 0.66–1.11 NS Dom: A NS
rs11205 5q23 HSD17B4 A/G 0.39 0.21 0.06–0.70 0.001 (0.61) Rec: ACP 0.44 1.08 0.84–1.39 NS Rec: ACP6 NS
rs2070874 5q31 IL4 C/T 0.16 2.16 1.27–3.67 0.005 (0.57) Dom: A 0.19 1.27 1.04–1.56 0.011 Dom: ACP6 0.047
rs1799964 6p21 TNF/LTA T/C 0.21 0.39 0.20–0.77 0.003 (0.57) Dom: A 0.20 0.91 0.74–1.13 0.20 Dom: ACP 0.44
rs4645959 8q24 C-MYC A/G 0.04 0 0.00-inf. 0.003 (0.57) Tre: ACP 0.02 1.23 0.84–1.78 NS Tre: A NS
rs1029153 † 10q11 CXCL12 T/C 0.31 0.22 0.07–0.75 0.005 (0.57) Tre: A
rs2839685 10q11 CXCL12 C/T 0.15 28.2 7.21–110.2 0.0003 (0.43) Rec: ACP 0.10 1.31 0.49–3.53 0.30 Rec: ACP6 0.34
rs2308327 10q26 MGMT A/G 0.13 0.32 0.13–0.78 0.004 (0.57) Tre: A 0.13 0.92 0.76–1.12 0.20 Tre: A 0.20
rs10778534 12q23 CRY1 T/C 0.36 2.21 1.19–4.12 0.008 (0.57) Dom: A 0.35 1.23 1.00–1.51 0.022 Dom: ACP 0.036
rs2494750 14q32 AKT1 C/G 0.07 0.22 0.07–0.70 0.001 (0.50) Tre: ACP 0.06 0.93 0.70–1.24 0.31 Tre: ACP 0.31
rs1799814 15q24 CYP1A1 C/A 0.05 0.13 0.03–0.57 0.0003 (0.26) Tre: ACP 0.03 1.47 0.86–1.28 NS Tre: ACP6 NS
rs25487 19q13 XRCC1 G/A 0.36 0.49 0.31–0.77 0.003 (0.57) Tre: A 0.35 0.95 0.83–1.08 0.20 Tre: A 0.40
rs915927 19q13 XRCC1 A/G 0.43 2.54 1.24–5.18 0.005 (0.57) Dom: A 0.44 0.88 0.71–1.08 NS Dom: ACP NS
rs5993891 22q11 ARVCF C/T 0.05 0.21 0.07–0.61 0.0004 (0.26) Dom: ACP 0.05 0.72 0.52–1.01 0.024 Dom: A 0.21
†

These SNPs were not evaluated in the Swedish cohort due to genotyping failure.

1

Major/minor allele

2

MAF: minor allele frequency, calculated from cases that did not die of prostate cancer.

3

Genetic model of best fit (Dom=dominant, Rec=recessive, Tre=trend) adjusted for age (A) alone, age + clinicopathological (ACP) factors (Gleason score, stage, diagnostic PSA level and primary treatment).

4

NS= not significant as the HR in the validation (Swedish) dataset is in the opposite direction as in the discovery (Seattle) dataset.

5

P-value for the Swedish dataset using the same best fitting genetic model and the same covariates as for the Seattle dataset.

6

Adjusted for age + clinicopathological factors as in footnote 3 above, excluding primary treatment.